Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2018 Publisher: Aspen Pharma Trading Limited, 3016 Lake Drive, Citywest Business Campus, Dublin 24, Ireland
Pharmacotherapeutic group: Antiinflammatory and Antirheumatic Products, Non-Steroids
ATC code: M01AB01
Indometacin has anti-inflammatory, antipyretic, and analgesic effects, it is an inhibitor of prostaglandin synthetase.
Indometacin is rapidly and almost completely absorbed on oral administration, and peak plasma levels are reached in ½ to 2 hours. Absorption is slowed but remains virtually complete when taken with food. About 90% is bound to plasma proteins. It appears to undergo enterohepatic cycling. It is metabolised partly by O-demthylation, partly by N-deacylation, and unchanged drug and metabolites are partly conjugated with glucoronic acid, in man, it is excreted unchanged and as it metabolites in both urine and faeces.
Administration of indomethacin to experimental animals at doses of 0.1-1.94 times the maximum recommended human clinical dose (MRHD) resulted in: i) maternal toxicity and death, ii) increased pre- and post-implantation loss, iii) increased embryotoxicity, foetal resorptions and foetal death, and iv) increased spontaneous abortion.
In pregnant mice and rats, indometacin treatment (during organogenesis) induced developmental defects including retarded foetal ossification and skeletal malformations at doses of 0.02-0.95 times the MRHD.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
